Co-Prenessa

Quick links

Choose a section

Quick links to important sections

Advertisements

Co-Prenessa

Advertisements
Advertisements

Overview of Co-Prenessa

Property Description
Active ingredients Perindopril and Indapamide
Form Tablet (Fixed-Dose Combination)
Pharmacological class Combination Antihypertensive
Origin Synthetic compounds
General purpose Management of High Blood Pressure

Co-Prenessa is a prescription-only medicine defined as a fixed-dose combination (FDC), meaning it is a single tablet containing two different active ingredients for oral administration. It is fundamentally an antihypertensive agent used for the long-term management of essential hypertension (high blood pressure). The strategy of combining two agents in one FDC is clinically recognized for providing improved blood pressure control compared to monotherapy. This approach is often utilized when patients require multiple agents to achieve their target pressure, simplifying their daily regimen.


What is the Composition of Co-Prenessa?

The medicine contains two INN active ingredients: Perindopril and Indapamide. These components belong to two entirely different pharmacological classes that ensure a dual-action approach. Perindopril is an Angiotensin-Converting Enzyme (ACE) Inhibitor, which is pharmacologically proven to promote the relaxation and widening of blood vessels.

Conversely, Indapamide is a thiazide-like diuretic, which works by helping the kidneys excrete excess sodium and water. The combination of an ACE inhibitor and a diuretic is a common and effective strategy in hypertension management, known under several trade names globally.


General Purpose of the Combination

The general purpose of Co-Prenessa is to provide a comprehensive and reliable management strategy for high blood pressure through a synergistic effect. The combination ensures that pressure is reduced by simultaneously addressing both the resistance in the blood vessels and the excess circulating fluid volume. This dual mechanism provides robust support for patients managing essential hypertension, as its fundamental benefit is the consistent, sustained maintenance of blood pressure within a healthier range.

Regulatory References

  1. NIH MedlinePlus
Advertisements

What side effects are possible with Co-Prenessa?

Possible Side Effects and Safety Information

The safety profile of Co-Prenessa (Perindopril/Indapamide) is organized according to standard regulatory classifications, grouping documented adverse reactions by frequency and the body systems affected. This information strictly reflects data contained within government regulatory documents, such as the Summary of Product Characteristics (SmPC).


Adverse Reaction Classifications

Frequency Classification Examples of Officially Documented Effects
Common (1 in 10 to 1 in 100 people) Dry, persistent cough, headache, dizziness, vertigo, asthenia (fatigue), muscle cramps, and various gastrointestinal disturbances.
Rare to Very Rare Angioedema, acute renal failure, severe skin reactions (e.g., Stevens-Johnson syndrome), pancreatitis, and hepatitis.

Serious Adverse Reactions

Official labeling lists Angioedema (swelling of the face, throat, and airways) as a rare but potentially life-threatening reaction that may occur at any time during treatment. Severe Hypotension (excessive low blood pressure) is also documented, and it is most likely to occur at the initiation of therapy or during dose adjustments. The combined action of the two active ingredients can also affect Metabolism and Nutrition, creating a risk for both hypokalemia (low potassium, linked to the diuretic) and hyperkalemia (high potassium, linked to the ACE inhibitor).


Population-Specific Safety Constraints

Use of this medicine is contraindicated in specific high-risk situations as defined by regulatory authorities. These include: individuals with a history of Angioedema related to previous ACE inhibitor use, severe hepatic impairment, or severe renal impairment (creatinine clearance less than 30 mL/min). Furthermore, use during the second and third trimesters of pregnancy is strictly forbidden due to the documented risk of fetal injury.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes a Co-Prenessa overdose primarily by its expected pharmacological effects, which include profound hypotension (excessively low blood pressure) and potential electrolyte disturbances. The most likely manifestations reported in regulatory documents are severe dizziness, confusion, and fainting ( passing out) as a result of low blood pressure. Severe outcomes may include shock or acute renal failure.


Immediate Actions Mandated by Regulators

Urgent medical help must be sought for specific serious symptoms. Immediate medical attention (emergency services) is required for trouble breathing, swelling of the face or throat, or loss of consciousness. This is particularly critical due to the risk of life-threatening angioedema ( swelling) linked to the Perindopril component, which can cause airway obstruction. The medicine must be discontinued immediately if laryngeal stridor or angioedema occurs.


Supportive Measures and Monitoring

Treatment is defined as symptomatic and supportive care. There is no specific antidote known. Regulatory information notes that Perindoprilat ( the active metabolite) can be dialysed as a supportive measure. Frequent monitoring of electrolytes (potassium) and renal function is required due to the potential for severe hypokalemia and other disturbances.

Advertisements

Therapeutic Uses of Co-Prenessa

What Co-Prenessa Treats: Main Uses and Benefits

Co-Prenessa is a medicine whose primary use is generally for managing essential hypertension (high blood pressure). The medicine is applied across domains where additional symptomatic support is needed for blood pressure management.

The product is commonly used for the treatment of essential hypertension, establishing its primary therapeutic domain.

This medicine is considered relevant for managing conditions characterized by periods of heightened symptoms and is often used when symptoms intensify and supportive relief is needed. The primary areas of use are generally for conditions presenting with systemic or localized discomfort. The medicine generally assists with maintaining functional stability and supports general well-being during symptomatic phases.


Key Therapeutic Support

Co-Prenessa is applied in scenarios where additional management of discomfort is required and generally helps ease the overall burden of symptoms related to systemic imbalance and heightened physiological activity.

By contributing to blood pressure management, the medicine helps support cardiovascular health over time, which is relevant in conditions marked by increased physiological stress. It helps address symptom clusters that may create noticeable physiological strain and may assist patients with maintaining functional stability.

Quick Fact: Relevant for easing symptoms related to Systemic Imbalance


Core Therapeutic Domains

  • Supporting Cardiovascular Stability: Contributes to easing the overall symptom load and helps to support cardiovascular health over time.
  • Easing Physiological Strain: Relevant for easing symptoms related to systemic imbalance, which may assist patients with maintaining functional stability.
  • Promoting Symptom Comfort: Offers symptomatic relief that may assist patients with maintaining functional stability and coping more steadily with symptom fluctuations.

Regulatory References

  1. Public Assessment Report from the Medicines Evaluation Board in the Netherlands
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Co-Prenessa?

This information reflects the official population eligibility and non-eligibility rules for Co-Prenessa (Perindopril/Indapamide) as defined in governmental regulatory documents.


Contraindicated Populations (Must Not Use)

Co-Prenessa is strictly contraindicated in several patient groups, including those with a history of Angioedema (Hereditary, Idiopathic, or related to a previous ACE inhibitor) and those with known hypersensitivity to Perindopril, Indapamide, or any sulfonamide derivative. Absolute exclusion applies to patients with Severe Renal Impairment (Creatinine Clearance <30 mL/min), Severe Hepatic Impairment, or pre-existing Hypokalaemia (low blood potassium levels). Concomitant use with certain medications, such as Sacubitril/Valsartan or Aliskiren (in diabetic or renally impaired patients), is also prohibited.


Age and Physiological Restrictions

Population Regulatory Status
Children and Adolescents (<18 years) Not Recommended (Safety and efficacy not established).
Pregnancy (Second/Third Trimester) Contraindicated. Use in the first trimester is Not Recommended.
Lactation (Breastfeeding) Contraindicated.

Conditional Use

Use is restricted and requires careful consideration in patients with Moderate Renal Impairment (Creatinine Clearance 30-60 mL/min) and those with certain Cardiovascular Conditions (e.g., Aortic Stenosis). Use in Older Adults is generally permitted but must be adjusted based on their renal function status.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for the fixed-dose combination Co-Prenessa is structured around regulatory restrictions concerning co-administration with other medicines and procedures. This information is derived strictly from government drug authority labeling.

Contraindicated Combinations and Procedures

The co-administration of Co-Prenessa with Sacubitril/Valsartan is formally contraindicated due to the significantly increased risk of angioedema. A strict 36-hour separation period must be observed between the last dose of one product and the initiation of the other. The use of Aliskiren is also contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment, due to the documented risk of hyperkalaemia. Specific extracorporeal treatments, such as certain high-flux dialysis procedures, are prohibited because of the risk of severe anaphylactoid reactions.


Other Documented Interactions

Co-administration with Potassium-sparing diuretics and Potassium supplements/salt substitutes is generally not recommended due to the increased, documented risk of hyperkalaemia. Use of Lithium is advised against, as it can cause reversible increases in serum lithium concentrations. Concomitant use with NSAIDs may reduce the antihypertensive effect and increase the risk of renal impairment. Additionally, the Indapamide component interacts with specific Torsades de Pointes-inducing agents, increasing the documented risk of QTc interval prolongation. The profile also includes specific population cautions, such as the risk of Indapamide precipitating hepatic encephalopathy in patients with severe hepatic impairment.

Advertisements

Mechanism of Action

Co-Prenessa comprises two active substances: perindopril and indapamide. Perindopril, a prodrug, is hydrolyzed in vivo to its active metabolite, perindoprilat. This metabolite functions as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), which is predominantly located on the endothelial surfaces of vascular tissue, particularly in the lungs and kidneys.

ACE catalyzes the conversion of angiotensin I to the potent vasoconstrictor angiotensin II and is responsible for the inactivation of the vasodilator bradykinin. By inhibiting ACE, perindoprilat reduces circulating and localized angiotensin II concentrations. This molecular modification leads to decreased stimulation of the angiotensin type 1 receptors (AT1) on vascular smooth muscle cells, resulting in vasodilation and a subsequent reduction in peripheral vascular resistance. Simultaneously, the reduced angiotensin II levels decrease the release of the mineralocorticoid aldosterone from the adrenal cortex, promoting natriuresis and reducing plasma volume. Indapamide, a thiazide-like diuretic, acts on the proximal segment of the distal convoluted tubule in the kidney. Indapamide is an inhibitor of the Na^+/ Cl^- cotransporter on the luminal membrane. This molecular interaction decreases the reabsorption of Na^+ and Cl^-, resulting in increased delivery of Na^+ and water to the collecting duct. This increase in Na^+ delivery, coupled with the systemic effects of perindopril, modulates fluid homeostasis and plasma volume. The combined action results in a coordinated reduction of both systemic vascular resistance and extracellular fluid volume.

Advertisements

Dosage and Administration Information

How to Use Co-Prenessa: Official Administration Guidelines

Co-Prenessa is a fixed-dose combination tablet containing perindopril and indapamide that is approved for oral use only. The medicine is designed for long-term use and must be administered according to specific procedural instructions.

Standard Dosing and Timing

Feature Instruction
Route of Administration Oral use (swallowing the tablet).
Frequency and Timing Once daily, preferably taken in the morning and before a meal (on an empty stomach).
Starting Dose Typically one 2 mg/0.625 mg tablet once a day.
Dose Adjustment If blood pressure is not adequately controlled, the dose may be increased, commonly to 4 mg/1.25 mg once daily, usually after one month of treatment.

Special Conditions and Constraints

The medicine is generally not intended for initial dose titration; use often follows prior evaluation with the individual components. The two strengths available are 2 mg/0.625 mg and 4 mg/1.25 mg; the lowest strength may be scored and can be divided for administration purposes.

Specific administration rules apply to certain patient groups. For older adults, treatment is typically initiated at the normal low dose (2 mg/0.625 mg), with a focus on monitoring kidney function. In patients with moderate renal impairment (creatinine clearance 30 to 60 mL/min), the maximum permitted dose is restricted to one 2 mg/0.625 mg tablet per day. Use in children and adolescents is generally not recommended.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Co-Prenessa


Evidence for Managing High Blood Pressure (Hypertension)

Research has explored the components of Co-Prenessa in research contexts focused on blood pressure. Studies monitored the impact of this combination on individuals with high blood pressure, a condition characterized by systemic or functional imbalance. These trials were primarily used in research exploring how symptoms change over time to assess if the medication was associated with changes in blood pressure readings compared to using a single component or an inactive treatment (placebo).

The findings describe patterns observed in the studies related to blood pressure. Research highlights changes measured during the study period, with findings indicating that the combination was associated with changes in blood pressure outcomes. Studies report how symptoms evolved in the observed populations over defined time intervals, indicating patterns related to blood pressure change.


Studies in Stable Coronary Artery Disease (CAD)

The components within Co-Prenessa was studied in research contexts involving stable coronary artery disease, which is a condition marked by functional limitations related to blood flow to the heart. Studies explored the relationship between this treatment regimen and long-term cardiovascular outcomes. Findings indicate that for the populations involved in these studies, the treatment was associated with patterns related to the monitored endpoints over the observation period.

It is important to remember that these research findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. Comparative evidence is lacking for certain head-to-head scenarios against other treatments.


What is Still Uncertain About Co-Prenessa

The overall research provides valuable context, but there are areas where research is ongoing and certainty remains low. One key gap is the need for more comparative evidence against all newer medications that are available today. While the data show patterns related to blood pressure changes and cardiovascular endpoints, findings were mixed or inconsistent in certain small subgroups, and the subgroup findings are uncertain for many less-common patient profiles. Data for highly specific groups, such as children or women in pregnancy-related populations, remain insufficient, and the available evidence is limited.

Key Studies & References

  1. Product Monograph: pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine / indapamide)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Co-Prenessa (FAQ)


Q: What is the main purpose of taking Co-Prenessa?

Co-Prenessa is officially indicated for the treatment of essential hypertension, which is the term for long-term high blood pressure. Regulatory documents state that this is the primary purpose for which the medicine is approved.


Q: Is Co-Prenessa considered a blood pressure drug?

Yes, official product information describes Co-Prenessa as a medicine approved for the treatment of essential hypertension (high blood pressure). Its function is to help manage blood pressure levels long-term.


Q: What condition is Co-Prenessa most commonly prescribed for?

According to official sources, Co-Prenessa is prescribed for the treatment of essential hypertension. This means it is used to manage high blood pressure that has no specific identifiable cause.


Q: How quickly does Co-Prenessa typically start lowering blood pressure?

Official efficacy data indicates that the full effect of the medicine in lowering blood pressure is typically achieved within one month of starting the treatment. The intention of the medicine is to maintain this effect over the long term with continued use.


Q: Is Co-Prenessa used for anything other than high blood pressure?

Official regulatory documents indicate that the medicine's approved purpose is limited to the treatment of essential hypertension. No other specific indications are listed in the official product information.


Q: What is the usual duration of Co-Prenessa's effect?

Co-Prenessa is administered once daily, and official product information states that the blood pressure lowering effect is sustained for a full 24-hour period. This allows for consistent management of blood pressure with a single daily dose.


Q: Are there any common side effects people report when starting Co-Prenessa?

Official regulatory documents list several commonly reported side effects. These may include general symptoms such as dizziness, headache, fatigue, and the occurrence of a dry cough. These effects are generally observed when starting treatment.


Q: Does Co-Prenessa commonly cause dizziness or lightheadedness?

Yes, dizziness and headache are listed in official regulatory documents as common side effects. These symptoms are particularly noted to occur at the start of treatment.


Q: Can Co-Prenessa affect kidney function over time?

Official regulatory documents emphasize that monitoring of kidney function (creatinine levels) is essential throughout the course of treatment. This monitoring is particularly focused on older adults and patients with pre-existing kidney conditions to assess for changes over time.


Q: Is a dry cough a known side effect of Co-Prenessa?

Yes, a dry cough is a known and commonly reported side effect, according to official regulatory sources. This is specifically associated with the perindopril component of the medicine, which is an ACE inhibitor.


Q: What are the signs of a serious reaction to Co-Prenessa that require attention?

Official regulatory warnings describe a rare but serious reaction called angioedema. Signs include sudden swelling of the face, lips, tongue, or throat. This condition is classified as a medical emergency in official warnings.


Q: Does Co-Prenessa interact with pain relievers like ibuprofen or aspirin?

Official sources describe a potential interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include medicines like ibuprofen and high-dose aspirin. This interaction may potentially reduce the blood pressure lowering effect and increase the risk of kidney-related issues.


Q: Can I take Co-Prenessa if I am taking supplements like potassium or magnesium?

Official regulatory documents state that supplements containing potassium are listed as generally not recommended to be taken with this medicine. This restriction is due to the potential risk of developing dangerously high potassium levels in the blood.


Q: What types of food or drinks should be used with caution while taking Co-Prenessa?

Official product information notes that caution is warranted regarding the consumption of alcohol, as it can increase the blood pressure lowering effect of the medicine. Furthermore, the label contains warnings about consuming foods and supplements high in potassium due to the potential for adverse effects.


Q: Is Co-Prenessa known to interact with common cold or flu medicines?

Interactions are possible with certain non-prescription medicines. Official documents specifically note potential interactions with drugs that contain NSAIDs (pain relievers) or other ingredients that affect blood pressure, such as decongestants found in some cold and flu remedies.


Q: Is it necessary to avoid alcohol while using Co-Prenessa?

Official regulatory documents contain a statement of caution regarding the use of alcohol while taking this medicine. Alcohol may potentially increase the blood pressure lowering effect of Co-Prenessa.


Q: Who is generally considered eligible to use Co-Prenessa?

Co-Prenessa is indicated for adults who have been diagnosed with essential hypertension (high blood pressure). Eligibility is also determined by the absence of specific medical conditions listed as contraindications in the official product information.


Q: Are there specific medical conditions that prevent someone from using Co-Prenessa?

Yes, official documents list several conditions which are classified as contraindications (reasons the medicine should not be used). These conditions include severe liver or kidney problems, a history of angioedema (serious swelling) related to an ACE inhibitor, and being in the second or third trimester of pregnancy.


Q: Can patients with diabetes take Co-Prenessa?

The regulatory label includes specific warnings and detailed monitoring recommendations for use in patients with diabetes. Close monitoring is necessary because the medicine may affect metabolic function, including blood sugar levels.


Q: Is Co-Prenessa considered appropriate for older adults?

Yes, the medicine is described in official documents as generally usable for older adults. However, treatment typically begins at the normal low dose, and there is an emphasis on close monitoring of kidney function during use.


Q: Can women who are pregnant or planning to be pregnant use Co-Prenessa?

Use of the medicine is strongly not recommended during the first three months of pregnancy. It is officially contraindicated, meaning its use is precluded, during the second and third trimesters due to potential risk to the fetus.


Q: What are the restrictions on Co-Prenessa use for people with severe liver problems?

Official regulatory documents state that Co-Prenessa is contraindicated in patients with severe hepatic impairment. This classification indicates the medicine is not appropriate for individuals with severe liver problems.


Q: Has Co-Prenessa been widely studied in large clinical trials?

Regulatory documents confirm that the medicine's use in managing hypertension is supported by the results of clinical studies. The official product information cites this research basis for its approved use.


Q: Are there long-term studies available on the use of Co-Prenessa?

Yes, official regulatory information indicates that the efficacy and safety of the combination have been demonstrated in long-term clinical studies. This research supports its ongoing use for chronic hypertension management.


Q: What is the typical research basis for using a combination medicine like this?

Official regulatory summaries cite clinical studies that demonstrate an additive blood pressure lowering effect when combining the two active ingredients. This combined benefit is the primary research basis for its formulation.


Q: What happens if a dose of Co-Prenessa is missed?

The patient information leaflet generally states that if a dose is missed, the standard procedure is to disregard the missed dose. The next dose is typically taken at the usual time, without taking a double dose to compensate.


Q: Is it normal to feel more tired after starting Co-Prenessa?

Yes, fatigue or tiredness is listed in official regulatory documents among the commonly reported side effects of the medicine.


Q: Why is it important for blood pressure to be monitored while taking Co-Prenessa?

Monitoring is described as essential to check for potential safety concerns, such as changes in electrolyte levels (like potassium) and kidney function. This information helps ensure the dose remains appropriate for the patient.


Q: Is there a known effect of Co-Prenessa on heart rate?

Official documents list potential effects on heart rate. Possible side effects include palpitations or, in some cases, bradycardia (a slow heart rate).


Q: Does Co-Prenessa help protect against heart attack or stroke according to research?

Regulatory information states that clinical studies have shown blood pressure reduction with the components of this medicine is associated with a reduction in overall cardiovascular risk. This covers the potential for heart attack or stroke.


Q: Can Co-Prenessa affect blood sugar levels?

The indapamide component of the medicine may affect metabolic function. Official documents indicate the need for caution and monitoring for changes in blood sugar levels, particularly for patients with diabetes.


Q: Is Co-Prenessa safe to stop suddenly?

Treatment for high blood pressure is typically considered long-term management. Official patient information generally states that, as hypertension treatment is often long-term, abrupt cessation of the medicine is typically avoided and not recommended without medical review.


Q: How does a doctor decide which strength of Co-Prenessa to prescribe?

The regulatory guidance states that the initial starting dose is usually the lowest available strength. The ultimate choice of dose depends on the patient's prior history with hypertension treatment and their current need for further blood pressure control.


Q: Are there any routine blood tests required while taking Co-Prenessa?

Yes, official documents describe that regular blood tests are necessary to monitor safety during treatment. These tests primarily check levels of serum potassium and creatinine, which is an indicator of kidney function.


Q: What should a patient do if they notice swelling in their hands or feet while on Co-Prenessa?

The regulatory label notes that swelling of the face, lips, tongue, or throat (angioedema) is a rare but serious side effect that requires attention. The regulatory label notes that this condition is a medical emergency; therefore, if it occurs, the medicine is typically discontinued and immediate medical evaluation is necessary.


Q: Can Co-Prenessa cause changes in sleep patterns?

Yes, official product information lists sleep disturbances (such as difficulty falling asleep) among the reported side effects of the medicine.


Q: Does Co-Prenessa have a known effect on libido?

Regulatory documents list impotence or sexual dysfunction as an uncommon possible side effect of the medicine.


Q: Is Co-Prenessa commonly used alongside other heart medications?

The regulatory label specifies certain other cardiovascular drugs that are not recommended or require special caution when used alongside Co-Prenessa. This indicates that interactions with certain heart medicines are a necessary consideration.


Q: What should be done in case of accidentally taking too much Co-Prenessa?

Official regulatory documents describe that accidental ingestion of excess medicine constitutes a medical emergency. Evaluation by a healthcare professional is necessary for symptoms of overdose, which often include profound lowering of blood pressure.


Q: What are the typical storage conditions recommended for Co-Prenessa tablets?

The official label provides specific storage instructions. The tablets are to be stored below a certain temperature and are to be kept in the original blister packaging to protect them from moisture.


Q: Are there any known differences in how Co-Prenessa affects different ethnic groups?

The regulatory label contains specific safety warnings regarding the potential for an increased risk of a serious reaction called angioedema in certain ethnic groups. This risk is noted to be higher for Black patients.


Q: Is Co-Prenessa commonly associated with elevated uric acid levels?

The indapamide component, which is a diuretic, may cause increases in uric acid levels. This is listed in official documents as a possible side effect.


Q: Does Co-Prenessa make a person sensitive to the sun?

Official regulatory documents list photosensitivity reactions as an uncommon or rare side effect of the medicine. This means some users may experience increased skin sensitivity to the sun.

Advertisements

How should Co-Prenessa be stored and disposed of?

How to Store and Dispose of Co-Prenessa

Storage and disposal of Co-Prenessa (perindopril/indapamide) must follow official regulatory requirements to maintain product stability and ensure environmental safety.

Storage Requirements

The tablets must be stored at a temperature not above 30°C and must be kept from freezing. Protection from environmental factors is mandatory; the medicine must be stored in the original package to protect from moisture and must be kept away from light. As a critical safety requirement, the medication must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused tablets must be discarded properly. Regulatory guidelines prohibit flushing medications down the toilet or pouring them into a drain. For safe disposal, patients should consult a pharmacist or a local waste disposal company for instructions on returning the unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-Prenessa found in:

A-Z Index: